“Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks”
May 21, 2024
“Sutro Biopharma (STRO)… “We think that luvelta has the potential to treat up to 80% of PROC patients, a significant improvement over the ~30% eligible for AbbVie’s Elahere (approved FolRα ADC)…
Overall, the Strong Buy consensus rating on STRO is based on 10 recent analyst reviews, including 9 Buys and 1 Hold. The shares are selling for $4.01 and their $11.44 average price target suggests that the stock will gain 185% in the next 12 months. (See STRO stock forecast)…
Avidity Biosciences (RNA)…
Looking ahead, the analyst rates RNA shares as a Buy, and his $40 price target indicates room for an upside potential of 35.5% on the one-year horizon. (To watch Meacham’s track record, click here)
A bullish take is no outlier here; RNA stock has 7 unanimously positive analyst reviews behind its Strong Buy consensus rating. The stock is currently trading for $29.50 and has an average price target of $42.67, for a 45% upside potential this coming year. (See RNA stock forecast)…”
https://finance.yahoo.com/news/bank-america-predicts-200-surge-130313930.html
